

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

The prevalence and incidence of myalgic encephalomyelitis/chronic fatigue syndrome in Europe: the EURO-epiME study from the European network EUROMENE. A protocol for a systematic review.

Journal:	BMJ Open
Manuscript ID	bmjopen-2017-020817
Article Type:	Protocol
Date Submitted by the Author:	20-Dec-2017
Complete List of Authors:	Estévez-López, Fer; University of Granada, Department of Physical Education and Sport, Faculty of Sport Sciences; Utrecht University, Department of Psychology, Faculty of Social and Behavioural Sciences Castro-Marrero, Jesus; Vall d'Hebron University Hospital, CFS/ME Unit, Universitat Autònoma de Barcelona Wang, Xia; University of East Anglia Bakken, Inger Johanne; Norwegian Institute of Public Health Ivanovs, Andrejs; Rigas Stradinas Universitate Nacul, Luis ; London School of Hygiene and Tropical Medicine Sepulveda, Nuno; London School of Hygiene and Tropical Medicine Strand, Elin; Oslo universitetssykehus Ulleval Pheby, Derek; Buckinghamshire New University Alegre, Jose; Vall d'Hebron University Hospital, CFS/ME Unit, Universitat Autònoma de Barcelona Scheibenbogen, Carmen; Charite - Universitatsmedizin Berlin Institut fur Medizin- Pflegepadagogik und Pflegewissenschaft Shikova-Lekova, Evelina; Natsionalen tsentar po zarazni i parazitni bolesti Lorusso, Lorenzo; A.S.S.T. della Franciacorta Capelli, Enrica; Universita degli Studi di Pavia Facolta di Medicina e Chirurgia Slobodan, Sekulic; Univerziteta u Novom Sadu Medicinski Fakultet Lacerda, Eliana; London School of Hygiene & Tropical Medicine Murovska, Modra; Rigas Stradinas Universitate

SCHOLARONE[™] Manuscripts

BMJ Open

The prevalence and incidence of myalgic encephalomyelitis/chronic fatigue syndrome in Europe: the EURO-epiME study from the European network EUROMENE. A protocol for a systematic review.

Fernando Estévez-López¹, Jesús Castro-Marrero², Xia Wang³, Inger J Bakken⁴, Andrejs Ivanovs⁵, Luis Nacul⁶, Nuno Sepulveda⁶, Elin B Strand⁷, Derek Pheby⁸, Jose Alegre², Carmen Scheibenbogen⁹, Evelina Shikova-Lekova¹⁰, Lorenzo Lorusso¹¹, Enrica Capelli¹², Sekulic Slobodan¹³, Eliana Lacerda^{6,*}, Modra Murovska^{14,*}

¹Department of Psychology, Faculty of Social and Behavioural Sciences, Utrecht University, Utrecht, The Netherlands; and Department of Physical Education and Sport, Faculty of Sport Sciences, University of Granada, Granada, Spain; ²Vall d'Hebron University Hospital, CFS/ME Unit, Universitat Autònoma de Barcelona, Barcelona, Spain; ³Norwich Medical School, University of East Anglia, Norwich, UK; ⁴Norwegian Institute of Public Health, Oslo, Norway; ⁵Statistics Unit, Riga Stradins University, Latvia; ⁶Department of Nutrition and Public Health Interventions Research, London School of Hygiene & Tropical Medicine, London, UK; ⁷Oslo University Hospital, Oslo,

Norway; ⁸Faculty of Health and Society, Buckinghamshire New University, High Wycombe, UK; ⁹Institute for Medical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany; ¹⁰Department of Virology, National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria; ¹¹A.S.S.T. della Franciacorta, Chiari, Italy; ¹²Department of Earth and Environmental Sciences, University of Pavia, Pavia, Italy; Medical Faculty Novi Sad, University of Novi Sad, Novi Sad, Serbia; ¹⁴August Kirchenstein Institute of

Microbiology and Virology, Riga Stradins University, Riga, Latvia. * E Lacerda and M Murovska equally contributed to this work.

Correspondence concerning this article should be addressed to: Fernando Estévez-López, Postdoctoral researcher, Department of Psychology, Faculty of Social and Behavioural Sciences, Utrecht University, Utrecht, The Netherlands. Postal address: Heidelberglaan 1, 3584 CS, Utrecht, The Netherlands. Phone: (+31) 30 253 4700. Email: F.Estevez-Lopez@uu.nl

Running head: Protocol of the EURO-epiMe study

tor beer terrier only

ABSTRACT

Introduction. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is characterized by severe fatigue lasting for at least 6 months. Studies on ME/CFS in Europe only include single countries and, therefore, the prevalence and incidence of ME/CFS in Europe (as a whole) is unknown. One of the purposes of the European Network on ME/CFS (EUROMENE; EU-funded COST Action; Reference number: 15111) is to address this gap in knowledge. We will systematically review the literature reporting figures from European countries to provide a robust summary and identify new challenges.

Methods and analysis. We will systematically search the literature databases Scopus, PubMed, and Web of Science. No language or year of publication restriction will be applied. Two independent reviewers will search, screen, and select studies as well as extract data about their main characteristics and evaluate their methodological and reporting quality. When disagreements emerge, the reviewers will discuss to reach a consensus. We plan to produce a narrative summary of our findings as we anticipate that studies are scarce and heterogeneous. The possibility of performing meta-analyses will be discussed in a EUROMENE meeting (i.e., February 8, 2018, in Sofia, Bulgaria). **Ethics and dissemination.** Ethical approval is not required as only publicly available data will be included. Findings will be described in EUROMENE reports, published in peer-reviewed journal(s), and presented at conferences. The findings will be also communicated to policymakers, healthcare providers, people with ME/CFS and other sections of society through regular channels including the mass-media.

PROSPERO registration number: CRD42017078688.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- To our knowledge, this will be the first review on the prevalence and incidence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in Europe.
- We will include validated ME/CFS case definitions and the whole lifespan. Studies based on self-report will be excluded.
- A potential limitation of this review is the possible small number of studies available and their high heterogeneity.
- This review will identify new challenges in the field, and will indicate whether more data on the prevalence and incidence of ME/CFS in Europe as a whole or in single countries are required.

BMJ Open

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) has heterogeneous clinical features and is characterized by severe fatigue lasting for at least 6 months, that is medically unexplained and not relieved by resting [1]. Consequently, ME/CFS often imposes a huge burden on daily life with negative impacts on health-related quality of life, labour status, and social and familial relationships [2–4]. Societal disbeliefs may add to the burden for people with ME/CFS [3,5].

For several reasons, ME/CFS is a challenge for scientists. Firstly, to date, the features of ME/CFS are poorly defined. For instance, an intense physical discomfort (i.e., malaise) along with flares of ME/CFS symptoms (lasting for longer than 24 hours) is observed after physical exertion [6]. However, whether post-exertional malaise is a distinctive feature of ME/CFS is not yet fully agreed [7]. Secondly, related to the lack of consensus on its defining features, a large number of disparate criteria for the diagnosis of ME/CFS are currently used worldwide [8]. Indeed, the most common scenario is to diagnose ME/CFS after exclusion of other diseases [9–11,4,12,13]. Thirdly, as different diagnostic criteria are used, ME/CFS prevalence and incidence figures are highly variable across studies. For instance, within an Icelandic study [14], the prevalence of ME/CFS ranged from 0 to 5% by means of the Lloyd et al [15] or Holmes et al [16] criteria.

To address the above-mentioned caveats and others it is imperative to understand comprehensively ME/CFS. With this purpose, the European Network on ME/CFS (EUROMENE) was established. This (EU-funded COST Action; Reference number: 15111) multidisciplinary network involves patients, stakeholders, researchers, clinicians, and industry. We intend to align ME/CFS research within the established landscape of European biomedical research by developing additional proposals to the

new H2020 and further Framework programme collaborative research projects. Further information about the EUROMENE network is available at: http://www.cost.eu/COST_Actions/ca/CA15111 and http://www.euromene.eu/).

EUROMENE consists of six coordinated working groups. Working group 1 focuses on the epidemiology of ME/CFS and leads the EUROpean Epidemiological Study for ME/CFS (EURO-EpiME study). One specific aim of this study is to estimate the prevalence and incidence of ME/CFS in Europe. As a first step, we will systematically review the available literature from European countries in order to provide a robust summary and identify new challenges on the field. It seems likely that more data on the prevalence and incidence of ME/CFS will be needed, both for Europe as a whole and within the European countries. Previously, systematic reviews have been conducted including studies from many parts of the world [17–19]. However, these previous reviews: (i) were conducted more than 5 years ago [20], (ii) did not report the incidence of ME/CFS, and (iii) did not include children or adolescents.

Objective

We aim to conduct a systematic review and, if possible, meta-analyses to determine the prevalence and incidence of ME/CFS in Europe.

Review question

- 1. What is the prevalence of ME/CFS in Europe?
- 2. What is the incidence of ME/CFS in Europe?

METHODS

Inclusion criteria

- 1. Studies reporting the prevalence of ME/CFS irrespective of age groups.
- 2. Studies from European countries.
- 3. Studies in community or primary care settings.

Exclusion criteria

- 1. Studies without primary data (e.g., reviews).
- 2. Studies conducted in biased samples (e.g., vaccines, virus infection, veterans).
- 3. Studies based on self-report of the diagnosis of ME/CFS.
- 4. Studies with an inappropriate case definition (i.e., either CFS-like illness or the Oxford criteria).
- 5. Duplicate reports. When populations are overlapping, the study with the largest sample size will be included.

No language or year of publication restriction will be applied.

Search strategy for identifying relevant studies

The search strategy will consist of two stages: a primary systematic literature search on three electronic databases and a complementary search.

The primary systematic literature search on electronic databases

Two independent reviewers (F.E.-L. and J.C.-M.) will perform a primary electronic search in PubMed, Scopus and Web of Science on January 9, 2018. Table 1 shows the search strategy.

The complementary search

We will conduct a twofold complementary search as follows: first, we will perform a backward- (by checking reference lists) and forward- (by checking citations) search of the works included in the present review; and second, grey literature will be addressed

by contacting – via email - all the members of EUROMENE to provide, if available, prevalence rates, incidence rates or both of ME/CFS in their countries according to national registers, publications in their own languages, or any other accessible source.

Selection of studies for inclusion to the review

Two independent researchers (F.E.-L. and J.C.-M.) will screen records retrieved by the electronic search by titles/abstracts or full text of works for identifying potential studies and their suitability. When disagreements emerge between the two independent researchers, consensus will be obtained through discussion or when required, the opinion of a third researcher (I.J.B.) will be considered.

Assessment of methodological quality and reporting of data

The methodological quality of the eligible studies will be evaluated with the Joanna Briggs Institute-Checklist for Prevalence Studies [21]. Before applying it, six members of the research team (i.e., F.E.-L., L.N., J.A., S.S., E.L., and M.M.) will develop an agreed appraisal of the tool. This appraisal will be published with the review as supplementary information. The reporting quality of the eligible studies will be evaluated uisng the observational studies in epidemiology (STROBE) checklist [22]. Two independent researchers (i.e., A.I. and X.W.) will evaluate the methodological and reporting quality of the included works. When controversies emerge, studies will be discussed with two other members of the team in order to reach a consensus (i.e., E.B.S. and D.P. for methodological and reporting quality, respectively). The quality assessment will be considered when discussing the findings.

Data extraction and management

To manage the retrieved records from the electronic search, we will use the Mendeley Desktop. Two independent researchers (F.E.-L. and A.I.) will extract the following relevant data from the included studies: reference (authors and year of publication),

BMJ Open

country (city or region when relevant), design (i.e., general population online survey), total sample size (*n* and % of women), age range, setting (e.g., primary care), case definition (i.e., diagnosis criteria), dates of data collection, overall prevalence or incidence and prevalence or incidence by gender and age groups (when available). When discrepancies emerge in the coding between the two researchers results will be discussed with two other members of the team (i.e., N.S.) to reach a consensus.

Data synthesis and analysis

We anticipate that studies on the prevalence and incidence of ME/CFS in Europe will prove to be scarce and heterogeneous. The preliminary findings of the review will be presented in a EUROMENE meeting (i.e., February 8, 2018, in Sofia, Bulgaria) where we will discuss the appropriateness of performing meta-analyses.

A narrative (descriptive) synthesis is planned if meta-analyses are not feasible. We will pay special attention to possible factors related to heterogeneity of the findings (e.g., diagnostic criteria, quality of the study) in order to find patterns that should be considered in future research. Attention will be also paid to the characteristics of the studied populations (e.g., age group, gender).

We will undertake meta-analyses only where pooling of quantitative data is possible. The meta regression analysis will be performed to investigate the sources of heterogeneity of any ME/CFS pooled prevalence estimate.

Presentation and reporting of results

We will report the findings of the present literature review in accordance with the preferred reporting items for systematic reviews and meta-analyses (i.e., the PRISMA statement [23]). A flow diagram (Figure 1) will illustrate the process of study selection from retrieved records to included studies. For transparency purposes, supplementary files will show which studies were excluded at every stage of the review.

In accordance with the data extraction, a table will show the main characteristics of the studies included. Information on the quality of the methodology and reporting of the studies will also be available.

If meta-analyses are performed, we plan using comprehensive meta-analysis (CMS) to combine data of prevalence or incidence from different studies to estimate the mean effect. We will select an appropriate model in terms of studies that we include and calculate pooled ME/CFS prevalence and incidence. We will compare the results of random-effects and fixed-effect meta-analyses in sensitivity analyses.

Ethics and dissemination

As systematic reviews use publicly available data, no formal ethical review and approval is needed. The findings of this systematic review will address a specific aim of the European network EUROMENE (i.e., to summarise the available data of the prevalence and incidence of ME/CFS in Europe). The findings will be included in EUROMENE reports and published in a paper in a peer-reviewed journal and presented at conferences and meetings.

The findings of the present systematic review will be widely communicated to society using mass media (e.g., interviews on radio, newspaper, television and the Internet). Since our findings may have an impact on policy and healthcare practice, we will also present them to policymakers and healthcare providers. We will present our findings to patients with ME/CFS (e.g., by direct communication with representative patient organisations, and by giving talks to local associations of people with ME/CFS).

AUTHORS' CONTRIBUTIONS

FE-L, JC-M, XW, EL, and MM designed the protocol. FE-L drafted the manuscript. FE-L, JC-M, XW, IJB, AI, LN, NS, EBS, DP, JA, CS, ES-L, LL, EC, SS, EL, MM revised and approved the final version of the manuscript. MM and EL are the chair and vice chair of the EUROMENE action, respectively.

ACKNOWLEDGMENTS

The present protocol of systematic review was agreed in a EUROMENE meeting in Belgrade (Serbia) on September 7, 2017. We thank all the participants for their active participation and valuable suggestions.

FUNDING

This work was supported by the COST (Action CA 15111: The European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (EUROMENE), the Spanish Ministry of Economy and Competitiveness [BES-2014-067612 to F.E.-L.], the Bulgarian National Science Fund [ДКОСТ 01/9 to E.S.]. The funders of the present study did not have any role in the design, decision to publish, or preparation of the protocol.

Competing interests: None declared.

REFERENCES

- Carruthers B, Jain AK, De Meirleir KL, Peterson DL, Klimas NG LA. Myalgic encephalomelitis/chronic fatigue syndromw: clinical working case definiton, diagnostic and treatment protocols. *J Chronic Fatigue Syndome* 2003;11:7–115.
- 2 Lowry TJ, Pakenham KI. Health-related quality of life in chronic fatigue syndrome: Predictors of physical functioning and psychological distress. *Psychol Health Med* 2008;13:222–38. doi:10.1080/13548500701335698
- 3 de Carvalho Leite JC, de L Drachler M, Killett A, *et al.* Social support needs for equity in health and social care: a thematic analysis of experiences of people with chronic fatigue syndrome/myalgic encephalomyelitis. *Int J Equity Health* 2011;**10**:46. doi:10.1186/1475-9276-10-46
- 4 Nacul LC, Lacerda EM, Campion P, *et al.* The functional status and well being of people with myalgic encephalomyelitis/chronic fatigue syndrome and their carers. *BMC Public Health* 2011;**11**:402. doi:10.1186/1471-2458-11-402
- Raine R, Carter S, Sensky T, *et al.* General practitioners' perceptions of chronic fatigue syndrome and beliefs about its management, compared with irritable bowel syndrome: qualitative study. *BMJ* 2004;**328**:1354–7. doi:10.1136/bmj.38078.503819.EE
- McManimen SL, Sunnquist ML, Jason LA. Deconstructing post-exertional malaise: An exploratory factor analysis. J Health Psychol 2016;:1359105316664139. doi:10.1177/1359105316664139
- Jason LA, Evans M, So S, *et al.* Problems in defining post-exertional malaise. J
 Prev Interv Community 2015;43:20–31. doi:10.1080/10852352.2014.973239
- 8 Nacul L, Lacerda EM, Kingdon CC, *et al.* How have selection bias and disease misclassification undermined the validity of myalgic encephalomyelitis/chronic

BMJ Open

fatigue syndrome studies? *J Health Psychol* 2017;:1359105317695803. doi:10.1177/1359105317695803

- 9 Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994;121:953–9. doi:10.7326/0003-4819-121-12-199412150-00009
- Carruthers BM, van de Sande MI, De Meirleir KL, et al. Myalgic encephalomyelitis: International Consensus Criteria. J Intern Med 2011;270:327–38. doi:10.1111/j.1365-2796.2011.02428.x
- Krumina A, Vasiljeva G, Ivanovs A, *et al.* Assessment of Value of Fatigue
 Severity and Symptoms in Patients with Chronic Fatigue Syndrome/Myalgic
 Encephalomyelitis and Fibromyalgia. *Br J Med Med Res* 2014;4:5866–77.
 doi:10.9734/BJMMR/2014/12225
- 12 Reeves WC, Lloyd A, Vernon SD, *et al.* Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. *BMC Health Serv Res* 2003;**3**:25. doi:10.1186/1472-6963-3-25
- Arpino C, Carrieri MP, Valesini G, *et al.* Idiopathic chronic fatigue and chronic fatigue syndrome: a comparison of two case-definitions. *Ann Ist Super Sanita* 1999;35:435–41.http://www.ncbi.nlm.nih.gov/pubmed/10721210 (accessed 6 Nov2017).
- 14 Líndal E, Stefánsson JG, Bergmann S. The prevalence of chronic fatigue syndrome in Iceland - a national comparison by gender drawing on four different criteria. *Nord J Psychiatry* 2002;**56**:273–7. doi:10.1080/08039480260242769
- Lloyd AR, Wakefield D, Boughton C, *et al.* What is myalgic encephalomyelitis?
 Lancet (London, England) 1988;1:1286–7. doi:10.1016/S0140-6736(88)92107-1

Holmes GP, Kaplan JE, Gantz NM, *et al.* Chronic fatigue syndrome: a working case definition. *Ann Intern Med* 1988;108:387–9. doi:10.1059/0003-4819-108-3-387

- 17 Ranjith G. Epidemiology of chronic fatigue syndrome. Occup Med (Lond)
 2005;55:13–9. doi:10.1093/occmed/kqi012
- 18 Dinos S, Khoshaba B, Ashby D, et al. A systematic review of chronic fatigue, its syndromes and ethnicity: prevalence, severity, co-morbidity and coping. Int J Epidemiol 2009;38:1554–70. doi:10.1093/ije/dyp147
- 19 Johnston S, Brenu EW, Staines DR, *et al.* The adoption of chronic fatigue syndrome/myalgic encephalomyelitis case definitions to assess prevalence: a systematic review. *Ann Epidemiol* 2013;23:371–6. doi:10.1016/j.annepidem.2013.04.003
- 20 Shojania KG, Sampson M, Ansari MT, et al. Updating Systematic Reviews. Agency for Healthcare Research and Quality (US) 2007. http://www.ncbi.nlm.nih.gov/pubmed/20734512 (accessed 13 Oct2017).
- 21 Munn Z, Moola S, Lisy K, *et al.* Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. *Int J Evid Based Healthc* 2015;**13**:147–53. doi:10.1097/XEB.00000000000054
- von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (London, England) 2007;370:1453–7. doi:10.1016/S0140-6736(07)61602-X
- 23 Moher D, Liberati A, Tetzlaff J, *et al.* Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009;**339**:b2535.

4	loi:10.1016/j.jcms.2010.11.001
5 6 7 8 9 10 11	
12 13 14 15 16 17	
18 19 20 21 22	
23 24 25 26 27 28	
29 30 31 32 33 34	
35 36 37 38 39	
40 41 42 43 44 45	
46 47 48 49 50 51	
52 53 54 55 56	
57 58 59 60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Figure 1. Flow diagram for study selection

WOS, web of science; ME/CFS, myalgic encephalomyelitis/chronic fatigue syndrome.

tor peer terien only

Database	Search terms combination
Scopus	({epidemiology} OR {prevalence} OR {incidence}) AND ({chronic
	fatigue syndrome} OR {myalgic encephalomyelitis} OR (4) OR (5))
	("Fatigue Syndrome, Chronic"[Mesh] AND (("Incidence"[Mesh]
PubMed	OR "Epidemiology" [Mesh] OR "epidemiology" [Subheading]) OR
	"Prevalence"[Mesh] OR "Cross-Sectional Studies"[Mesh]))
	("epidemiology" OR "prevalence" OR "incidence") AND ("chronic
Web of science	fatigue syndrome" OR "myalgic encephalomyelitis" OR "CFS/ME"
	OR "ME/CFS")
Mesh, medical su	ibject headings
Mesh, medical su	ubject headings




Figure 1. Flow diagram for study selection

423x423mm (300 x 300 DPI)



BMJ Open

The prevalence and incidence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Europe: the Euro-epiME study from the European network EUROMENE. A protocol for a systematic review.

Journal:	BMJ Open
Manuscript ID	bmjopen-2017-020817.R1
Article Type:	Protocol
Date Submitted by the Author:	22-Jun-2018
	Estévez-López, Fer; University of Granada, Department of Physical Education and Sport, Faculty of Sport Sciences; Utrecht University, Department of Psychology, Faculty of Social and Behavioural Sciences Castro-Marrero, Jesus; Vall d'Hebron University Hospital, CFS/ME Unit, Universitat Autònoma de Barcelona; Cornell University, Department of Molecular Biology and Genetics Wang, Xia; University of East Anglia Bakken, Inger Johanne; Norwegian Institute of Public Health Ivanovs, Andrejs; Rigas Stradinas Universitate Nacul, Luis ; London School of Hygiene and Tropical Medicine Sepulveda, Nuno; London School of Hygiene and Tropical Medicine Strand, Elin; Oslo universitetssykehus Ulleval Pheby, Derek; Buckinghamshire New University Alegre, Jose; Vall d'Hebron University Hospital, CFS/ME Unit, Universitat Autònoma de Barcelona Scheibenbogen, Carmen; Charite - Universitatsmedizin Berlin Institut fur Medizin- Pflegepadagogik und Pflegewissenschaft Shikova-Lekova, Evelina; Natsionalen tsentar po zarazni i parazitni bolest Lorusso, Lorenzo; A.S.S.T. della Franciacorta Capelli, Enrica; Universita degli Studi di Pavia Facolta di Medicina e Chirurgia Slobodan, Sekulic; University of Novi Sad, Department of Neurology, Medical Faculty Novi Sad Lacerda, Eliana; London School of Hygiene & Tropical Medicine Murovska, Modra; Rigas Stradinas Universitate
Primary Subject Heading :	Public health
Secondary Subject Heading:	Epidemiology
Keywords:	EPIDEMIOLOGY, EUROMENE, EURO-epiME, incidence, prevalence
Keywords:	EPIDEMIOLOGY, EUROMENE, EURO-epiME, incidence, prevalence bmitted by the author for peer review, but cannot be converted t

20180507PRISMA-P-che	ecklist.doc
	SCHOLARONE [™] Manuscripts

1	The prevalence and incidence of Myalgic Encephalomyelitis/Chronic Fatigue
2	Syndrome in Europe: the Euro-epiME study from the European network
3	EUROMENE. A protocol for a systematic review.
4	
5	Fernando Estévez-López ¹ , Jesús Castro-Marrero ² , Xia Wang ³ , Inger J Bakken ⁴ , Andrejs
6	Ivanovs ⁵ , Luis Nacul ⁶ , Nuno Sepulveda ⁶ , Elin B Strand ⁷ , Derek Pheby ⁸ , Jose Alegre ⁹ ,
7	Carmen Scheibenbogen ¹⁰ , Evelina Shikova-Lekova ¹¹ , Lorenzo Lorusso ¹² , Enrica
8	Capelli ¹³ , Slobodan Sekulic ¹⁴ , Eliana Lacerda ^{6,*} , Modra Murovska ^{15,*} , on behalf of the
9	European Network on ME/CFS (EUROMENE)
10	
11	¹ Department of Psychology, Faculty of Social and Behavioural Sciences, Utrecht
12	University, Utrecht, The Netherlands; Department of Physical Education and Sport,
13	Faculty of Sport Sciences, University of Granada, Granada, Spain; and School of Health
14	Sciences, Ulster University, Northern Ireland, UK; ² Vall d'Hebron University Hospital,
15	CFS/ME Unit, Universitat Autònoma de Barcelona, Barcelona, Spain; and Department
16	of Molecular Biology and Genetics, Cornell University, Ithaca, NY, USA; ³ Norwich
17	Medical School, University of East Anglia, Norwich, UK; ⁴ Norwegian Institute of
18	Public Health, Oslo, Norway; ⁵ Statistics Unit, Riga Stradins University, Latvia; ⁶
19	Department of Nutrition and Public Health Interventions Research, London School of
20	Hygiene & Tropical Medicine, London, UK; ⁷ National Advisory Unit on CFS/ME, Oslo
21	University Hospital, Oslo, Norway; ⁸ Faculty of Health and Society, Buckinghamshire
22	New University, High Wycombe, UK; ⁹ Vall d'Hebron University Hospital, CFS/ME
23	Unit, Universitat Autònoma de Barcelona, Barcelona, Spain; ¹⁰ Institute for Medical
24	Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany; ¹¹ Department of
25	Virology, National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria;

3 of 20		BMJ Open
	26	¹² A.S.S.T. della Franciacorta, Chiari, Italy; ¹³ Department of Earth and Environmental
	27	Sciences, University of Pavia, Pavia, Italy; ¹⁴ Department of Neurology, Medical Faculty
	28	Novi Sad, University of Novi Sad, Serbia; ¹⁵ August Kirchenstein Institute of
	29	Microbiology and Virology, Riga Stradins University, Riga, Latvia.
	30	
	31	[*] E Lacerda and M Murovska equally contributed to this work.
	32	
	33	Correspondence concerning this article should be addressed to: Fernando Estévez-
	34	López, Postdoctoral researcher, Department of Psychology, Faculty of Social and
	35	Behavioural Sciences, Utrecht University, Utrecht, The Netherlands. Postal address:
	36	Heidelberglaan 1, 3584 CS, Utrecht, The Netherlands. Phone: (+31) 30 253 4700.
	37	Email: <u>F.Estevez-Lopez@uu.nl</u>
	38	
	39	Running head: Protocol of the Euro-epiMe study
	40	
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml 2

41 ABSTRACT

Introduction. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a chronic disease involving central nervous system and immune system disorders, as well as cardiovascular abnormalities. ME/CFS is characterized by severe chronic fatigue lasting for at least 6 months, including such clinical symptoms as tender cervical or axillary lymph nodes, muscle pain, joint pain without swelling or redness, post-exertional malaise for more than 24 hours, and un-refreshing sleep. Studies on the epidemiology of ME/CFS in Europe only include single countries and, therefore, the prevalence and incidence of ME/CFS in Europe (as a whole) is unknown. One of the purposes of the European Network on ME/CFS (EUROMENE; EU-funded COST Action; Reference number: 15111) is to address this gap in knowledge. We will systematically review the literature reporting figures from European countries to provide a robust summary and identify new challenges.

Methods and analysis. We will systematically search the literature databases Scopus, PubMed, and Web of Science for studies published in the last 10 years (i.e., after 2007). No language restriction will be applied. Two independent reviewers will search, screen, and select studies as well as extract data about their main characteristics and evaluate their methodological and reporting quality. When disagreements emerge, the reviewers will discuss to reach a consensus. We plan to produce a narrative summary of our findings as we anticipate that studies are scarce and heterogeneous. The possibility of performing meta-analyses will be discussed in a EUROMENE meeting.

62 Ethics and dissemination. Ethical approval is not required as only publicly available 63 data will be included. Findings will be described in EUROMENE reports, published in 64 peer-reviewed journal(s), and presented at conferences. The findings will be also

1		
2 3	65	communicated to policymakers, healthcare providers, people with ME/CFS and other
4 5	66	sections of society through regular channels including the mass-media.
6 7	67	PROSPERO registration number: CRD42017078688.
8 9 10	68	
10 11 12	69	
13 14	70	
15 16	71	
17 18		
19 20		
21 22		
23 24		
25		
26 27		
28		
29 30		
31		
32 33		
34 35		
36		
37 38		
39		
40 41		
42 43		
44		
45 46		
47		
48 49		
50		
51 52		
53		
54 55		
56 57		
58		
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml 4

2	
4 5	
6	
7	
8 9 10	
10	
11 12	
13	
14 15	
16	
17 18	
19	
20 21	
22	
23 24	
25	
26 27	
20	
20 29 30	
31	
32 33	
34	
35 36	
37	
38 39	
40	
41 42	
43	
44 45	
46	
47 48	
49	
50 51	
52	
53 54	
55	
56 57	
58	
59 60	

1 h

72 STRENGTHS AND LIMITATIONS OF THIS STUDY

- 73 The main strengths of this protocol rely on its carefully designed search strategy,
- 74 inclusion and exclusion criteria, and time span coverage.
- 75 The search strategy will address the potential EU studies published in non-English 76 national languages, and we will include currently accepted ME/CFS case 77 definitions, to minimise selection bias.
- 78 Studies based on self-report will be excluded, and the search time of 10 years will 79 enable us to picture the ME/CFS occurrence in Europe.
- 80 The European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome • 81 (EUROMENE), a network of established researchers on ME/CFS, will conduct the 82 proposed systematic review, which can increase credibility and reliability of the 83 findings.
- 84 A potential limitation of this review may be a small number of studies available and 85 their potential high heterogeneity.
- 86
- 87

BMJ Open

88 INTRODUCTION

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) has heterogeneous clinical features and is characterized by severe fatigue lasting for at least 6 months, that is medically unexplained and not relieved by resting [1]. Consequently, ME/CFS often imposes a huge burden on daily life with negative impacts on health-related quality of life, labour status, and social and familial relationships [2–4]. Societal disbeliefs may add to the burden for people with ME/CFS [3,5].

For several reasons, ME/CFS is a challenge for scientists. Firstly, to date, the features of ME/CFS have been poorly defined. For instance, an intense physical discomfort (i.e., malaise) along with flares of ME/CFS symptoms (lasting for longer than 24 hours) is observed after minimum physical exertion [6]. However, whether post-exertional malaise is a distinctive feature of ME/CFS is not yet fully agreed [7]. Secondly, related to the lack of consensus on its defining features, a large number of disparate criteria for the diagnosis of ME/CFS are currently used worldwide [8]. Indeed, the most common scenario is to diagnose ME/CFS after exclusion of other diseases [4,9–13]. Thirdly, as different diagnostic criteria are used, ME/CFS prevalence and incidence figures are highly variable across studies. For instance, within an Icelandic study [14], the prevalence of ME/CFS ranged from 0 to 5% by means of the Lloyd et al [15] or Holmes et al [16] criteria, respectively.

107 To address the above-mentioned caveats and others it is imperative to 108 understand comprehensively ME/CFS. With this purpose, the European Network on 109 ME/CFS (EUROMENE) was established. This (EU-funded COST Action; Reference 110 number: 15111) multidisciplinary network involves patients, stakeholders, researchers, 111 clinicians, and industry. We intend to align ME/CFS research within the established 112 landscape of European biomedical research by developing additional proposals to the

new H2020 and further Framework programme collaborative research projects. Further
information about the EUROMENE network is available at:
http://www.cost.eu/COST_Actions/ca/CA15111 and http://www.euromene.eu/).

EUROMENE consists of six closely coordinated working groups. Working group 1 focuses on the epidemiology of ME/CFS and leads the European Epidemiological Study for ME/CFS (Euro-EpiME study). One specific aim of this study is to estimate the prevalence and incidence of ME/CFS in Europe. As a first step, we will systematically review the available literature from European countries in order to provide a robust summary and identify new challenges on the field. It seems likely that more data on the prevalence and incidence of ME/CFS will be needed, both for Europe as a whole and within the European countries. Previously, systematic reviews have been conducted including studies from many parts of the world [17–19]. However, these previous reviews: (i) were conducted more than 5 years ago [20], (ii) did not report the incidence of ME/CFS, and (iii) did not include children or adolescents.

Objective

128 We aim to conduct a systematic review and, if possible, meta-analyses to determine the

- 129 prevalence and incidence of ME/CFS in Europe.
- **Review question**
- 131 1. What is the prevalence of ME/CFS in Europe?
- 132 2. What is the incidence of ME/CFS in Europe?

1

60

135 Inclusion criteria 136 1. Studies reporting either the prevalence or incidence of ME/CFS, including any of 137 the following clinical diagnostic criteria – CDC-1994 [9], Canadian Consensus 138 Criteria [1], London Criteria [21], International Consensus Criteria [10], or Institute 139 of Medicine criteria [22], irrespective of age groups. 140 2. Studies from European countries. 141 3. Studies in community or primary care settings.

142 Exclusion criteria

METHODS

- 143 1. Studies without primary data (e.g., reviews).
- 144 2. Studies conducted in biased samples (e.g., vaccines, virus infection, veterans).
- 145 3. Studies based on self-report of the diagnosis of ME/CFS.
- 146 4. Studies with an inappropriate case definition (e.g., CFS-like illness or other clinical
- 147 criteria, such as the Oxford criteria due to lack of specificity).
- 148 5. Duplicate reports. When populations are overlapping, the study with the largest
- sample size will be included.
- 150 6. Studies published more than 10 years ago (i.e., before 2008)
- 151 No language restriction will be applied.
- 152 Search strategy for identifying relevant studies
- 153 The search strategy will consist of two stages: a primary systematic literature search on
- three electronic databases and a complementary search.
 - 155 The primary systematic literature search on electronic databases
- 156 Two independent reviewers (F.E.-L. and J.C.-M.) will perform a primary electronic
- 157 search in PubMed, Scopus and Web of Science on January 9, 2018. Table 1 shows the
- 158 search strategy.

The complementary search

We will conduct a twofold complementary search as follows: first, we will perform a backward- (by checking reference lists) and forward- (by checking citations) search of the works included in the present review; and second, grey literature will be addressed by contacting – via email - all the members of EUROMENE to provide, if available, prevalence rates, incidence rates or both of ME/CFS in their countries according to national registers, publications in their own languages, or any other publicly accessible source.

167 Selection of studies for inclusion to the review

Two independent researchers (F.E.-L. and J.C.-M.) will screen records retrieved by the electronic search by titles/abstracts or full text of works for identifying potential studies and their suitability. When disagreements emerge between the two independent researchers, consensus will be obtained through discussion or when required, the opinion of a third researcher (I.J.B.) will be considered.

173 Assessment of methodological quality and reporting of data

The methodological quality of the eligible studies will be evaluated with the Joanna Briggs Institute-Checklist for Prevalence Studies [23]. Before applying it, six members of the research team (i.e., F.E.-L., L.N., J.A., S.S., E.L., and M.M.) will develop an agreed appraisal of the tool. This appraisal will be published with the review as supplementary information. The reporting quality of the eligible studies will be evaluated using the observational studies in epidemiology (STROBE) checklist [24]. Two independent researchers (i.e., A.I. and X.W.) will evaluate the methodological and reporting quality of the included works. When controversies emerge, studies will be discussed with two other members of the team in order to reach a consensus (i.e., E.B.S.

BMJ Open

and D.P. for methodological and reporting quality, respectively). The qualityassessment will be considered when discussing the findings.

185 Data extraction and management

To manage the retrieved records from the electronic search, we will use the Mendeley Desktop. Two independent researchers (F.E.-L. and A.I.) will extract the following relevant data from the included studies: reference (authors and year of publication), country (city or region when relevant), design (i.e., general population online survey), total sample size (n and % of women, n and % of migrants), age range, setting (e.g., primary care), case definition (i.e., diagnosis criteria), dates of data collection, overall prevalence and/or incidence and prevalence and/or incidence by gender and age groups (when available). When discrepancies emerge in the coding between the two researchers' results, these will be discussed with another members of the team (i.e., N.S.) to reach a consensus.

196 Data synthesis and analysis

We anticipate that studies on the prevalence and incidence of ME/CFS in Europe will prove to be scarce and heterogeneous. The preliminary findings of the review will be presented in a EUROMENE meeting (i.e., September, 2018, in London, the UK) where we will discuss the appropriateness of performing meta-analyses.

A narrative (descriptive) synthesis is planned if meta-analyses are not feasible. We will pay special attention to possible factors related to heterogeneity of the findings in order to find patterns that should be considered in future research. For instance, we will discuss whether the prevalence or incidence of ME/CFS differ according to the case definition used to examine the figures. Attention will be also paid to the characteristics of the studied populations (e.g., age group, gender).

We will undertake meta-analyses only where pooling of quantitative data is possible. The meta regression analysis will be performed to investigate the sources of heterogeneity of any ME/CFS pooled prevalence and incidence estimate. The I^2 statistic will be used to investigate the heterogeneity. I^2 of 25%, 50%, and 75% will be appraised as low, moderate, and high, respectively [25].

Presentation and reporting of results

We will report the findings of the present literature review in accordance with the preferred reporting items for systematic reviews and meta-analyses (i.e., the PRISMA statement [26]). A flow diagram (Figure 1) will illustrate the process of study selection from retrieved records to included studies. For transparency purposes, supplementary files will show which studies were excluded at every stage of the review. If the present protocol needs amendments, they will be publicly available along with their rationale in the EUROMENE website: http://www.euromene.eu/

In accordance with the data extraction, a table will show the main characteristics of the
studies included. Information on the quality of the methodology and reporting of the
studies will also be available.

If meta-analyses are performed, we plan using comprehensive meta-analysis (CMS) to combine data of prevalence or incidence from different studies to estimate the mean effect. We will select an appropriate model in terms of studies that we include and calculate pooled ME/CFS prevalence and incidence. We will compare the results of random-effects and fixed-effect meta-analyses in sensitivity analyses.

BMJ Open

3
4
4 7
с С
6
7
8
9
10
11
12
13
14
14 15 16
16
16 17
17
18
19
20
21
22
23
24
25
26
27
28
20
30
31
32
33
34
35
36
36 37
38
39
40
41
42
43 44
45
46
47
48
49
50
51
52
53
54
55
56
50 57
58
59
60

232 Ethics and dissemination

As systematic reviews use publicly available data, no formal ethical review and approval is needed. The findings of this systematic review will address a specific aim of the European network EUROMENE (i.e., to summarise the available data of the prevalence and incidence of ME/CFS in Europe). The findings will be included in EUROMENE reports published in paper(s) in peer-reviewed journal(s) and presented at conferences and meetings.

The findings of the present systematic review will be widely communicated to society using mass media (e.g., interviews on radio, newspaper, television and the Internet). Since our findings may have an impact on policy and healthcare practice, we will also present them to policymakers and healthcare providers.

243 Patie

Patient and public involvement

EUROMENE is multidisciplinary network cooperating with patient organizations via Web platform. Patient organisations are benefiting from dedicated events, dedicated printed media and interaction through social media. We will present our findings to patients with ME/CFS (e.g., by direct communication with representative patient organisations, and by giving talks to local associations of people with ME/CFS). General public will be reached through the Action website, oral presentations and interviews.

- 251
- 252
- 253
- 254

256 AUTHORS' CONTRIBUTIONS

FE-L, JC-M, XW, EL, and MM designed the protocol. FE-L drafted the manuscript. FE-L, JC-M, XW, IJB, AI, LN, NS, EBS, DP, JA, CS, ES-L, LL, EC, SS, EL, MM revised and approved the final version of the manuscript. MM and EL are the chair and vice chair of the EUROMENE action, respectively. FE-L will be the guarantor of the review

262 ACKNOWLEDGMENTS

The present protocol of systematic review was agreed in a EUROMENE meeting in
Belgrade (Serbia) on September 7, 2017. We thank all the participants for their active
participation and valuable suggestions.

266 FUNDING

This work was supported by the COST (Action CA 15111: The European Network on
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (EUROMENE), the Spanish
Ministry of Economy and Competitiveness [BES-2014-067612 to F.E.-L.], the
Bulgarian National Science Fund [ДКОСТ 01/9 to E.S.]. The funders of the present
study did not have any role in the design, decision to publish, or preparation of the
protocol.

Competing interests: None declared.

ו ר	
2 3	
3 4	
5 6	
0 7	
/	
8	
9	
10	
11	
12	
13	
11 12 13 14 15 16 17 18	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35 36	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
50 59	
60	
00	

276 **REFERENCES**

- 277 1 Carruthers B, Jain AK, De Meirleir KL, Peterson DL, Klimas NG LA. Myalgic
 278 encephalomelitis/chronic fatigue syndromw: clinical working case definiton,
 279 diagnostic and treatment protocols. *J Chronic Fatigue Syndome* 2003;11:7–115.
- 280 2 Lowry TJ, Pakenham KI. Health-related quality of life in chronic fatigue
 281 syndrome: Predictors of physical functioning and psychological distress. *Psychol*282 *Health Med* 2008;13:222–38. doi:10.1080/13548500701335698
 - de Carvalho Leite JC, de L Drachler M, Killett A, *et al.* Social support needs for
 equity in health and social care: a thematic analysis of experiences of people with
 chronic fatigue syndrome/myalgic encephalomyelitis. *Int J Equity Health*2011;10:46. doi:10.1186/1475-9276-10-46
- Nacul LC, Lacerda EM, Campion P, *et al.* The functional status and well being of
 people with myalgic encephalomyelitis/chronic fatigue syndrome and their
 carers. *BMC Public Health* 2011;11:402. doi:10.1186/1471-2458-11-402
- Raine R, Carter S, Sensky T, *et al.* General practitioners' perceptions of chronic
 fatigue syndrome and beliefs about its management, compared with irritable
 bowel syndrome: qualitative study. *BMJ* 2004;**328**:1354–7.
 doi:10.1136/bmj.38078.503819.EE
 - McManimen SL, Sunnquist ML, Jason LA. Deconstructing post-exertional
 malaise: An exploratory factor analysis. *J Health Psychol*2016;:1359105316664139. doi:10.1177/1359105316664139
 - Z97 7 Jason LA, Evans M, So S, *et al.* Problems in defining post-exertional malaise. J
 298 *Prev Interv Community* 2015;43:20–31. doi:10.1080/10852352.2014.973239
 - 8 Nacul L, Lacerda EM, Kingdon CC, *et al.* How have selection bias and disease
 misclassification undermined the validity of myalgic encephalomyelitis/chronic

301 fatigue syndrome studies? *J Health Psychol* 2017;:1359105317695803.

- 302 doi:10.1177/1359105317695803
- Fukuda K, Straus SE, Hickie I, *et al.* The chronic fatigue syndrome: a
 comprehensive approach to its definition and study. International Chronic
 Fatigue Syndrome Study Group. *Ann Intern Med* 1994;121:953–9.
 doi:10.7326/0003-4819-121-12-199412150-00009
- 307 10 Carruthers BM, van de Sande MI, De Meirleir KL, *et al.* Myalgic
 308 encephalomyelitis: International Consensus Criteria. *J Intern Med* 2011;270:327–
 309 38. doi:10.1111/j.1365-2796.2011.02428.x
- Krumina A, Vasiljeva G, Ivanovs A, *et al.* Assessment of Value of Fatigue
 Severity and Symptoms in Patients with Chronic Fatigue Syndrome/Myalgic
 Encephalomyelitis and Fibromyalgia. *Br J Med Med Res* 2014;4:5866–77.
 doi:10.9734/BJMMR/2014/12225
 - Reeves WC, Lloyd A, Vernon SD, *et al.* Identification of ambiguities in the 1994
 chronic fatigue syndrome research case definition and recommendations for
 resolution. *BMC Health Serv Res* 2003;**3**:25. doi:10.1186/1472-6963-3-25
- Arpino C, Carrieri MP, Valesini G, *et al.* Idiopathic chronic fatigue and chronic
 fatigue syndrome: a comparison of two case-definitions. *Ann Ist Super Sanita*1999;**35**:435–41.http://www.ncbi.nlm.nih.gov/pubmed/10721210 (accessed 6
 Nov 2017).
 - 321 14 Líndal E, Stefánsson JG, Bergmann S. The prevalence of chronic fatigue
 322 syndrome in Iceland a national comparison by gender drawing on four different
 323 criteria. *Nord J Psychiatry* 2002;**56**:273–7. doi:10.1080/08039480260242769
 - Lloyd AR, Wakefield D, Boughton C, *et al.* What is myalgic encephalomyelitis? *Lancet (London, England)* 1988;1:1286–7. doi:10.1016/S0140-6736(88)92107-1

BMJ Open

1			
2 3	326	16	Holmes GP, Kaplan JE, Gantz NM, et al. Chronic fatigue syndrome: a working
4 5	327		case definition. Ann Intern Med 1988;108:387-9. doi:10.1059/0003-4819-108-3-
6 7	328		387
8 9	329	17	Ranjith G. Epidemiology of chronic fatigue syndrome. Occup Med (Lond)
10 11		17	2005; 55 :13–9. doi:10.1093/occmed/kgi012
12	330		2003, 55 .13–9. doi.10.1095/0ccilied/kq1012
13 14	331	18	Dinos S, Khoshaba B, Ashby D, et al. A systematic review of chronic fatigue, its
15 16	332		syndromes and ethnicity: prevalence, severity, co-morbidity and coping. Int J
17 18	333		<i>Epidemiol</i> 2009; 38 :1554–70. doi:10.1093/ije/dyp147
19 20	334	19	Johnston S, Brenu EW, Staines DR, et al. The adoption of chronic fatigue
21 22	335	-	syndrome/myalgic encephalomyelitis case definitions to assess prevalence: a
23	222		syndrome/myargic encepharomyenus case demintions to assess prevalence. a
24 25	336		systematic review. Ann Epidemiol 2013;23:371–6.
26 27	337		doi:10.1016/j.annepidem.2013.04.003
28 29	338	20	Shojania KG, Sampson M, Ansari MT, et al. Updating Systematic Reviews.
30	339		Agency for Healthcare Research and Quality (US) 2007.
31 32			
33 34	340		http://www.ncbi.nlm.nih.gov/pubmed/20734512 (accessed 13 Oct 2017).
35 36	341	21	Dowsett EG, Goudsmit E, Macintyre A SC. The National Task Force on Chronic
37 38	342		Fatigue Syndrome (CFS), Post Viral Fatigue Syndrome (PVFS), Myalgic
39 40	343		Encephalomyelitis (ME). Westcare 1994.
41			
42	344	22	Institute of Medicine IOM. Beyond Myalgic Encephalomyelitis/Chronic Fatigue
43	345		Syndrome: Redefining an Illness. Natl Acad Press 2015.
44 45	343		Syndrome. Redenning an inness. Nau Acau 17ess 2015.
46 47	346	23	Munn Z, Moola S, Lisy K, et al. Methodological guidance for systematic reviews
48	347		of observational epidemiological studies reporting prevalence and cumulative
49 50	240		incidence data but I Fuid Dread Harltha 2015,12,147,52
51	348		incidence data. Int J Evid Based Healthc 2015;13:147–53.
52 53	349		doi:10.1097/XEB.000000000000054
54 55 56	350	24	von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of
57 58			

2 3	351		Observational Studies in Epidemiology (STROBE) statement: guidelines for
4 5	352		reporting observational studies. Lancet (London, England) 2007;4:e296.
6 7	353		doi:10.1371/journal.pmed.0040296
8 9 10	354	25	Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-
11 12	355		analyses. BMJ 2003; 327 :557-60. doi:10.1136/bmj.327.7414.557
13 14	356	26	Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic
15 16	357		reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
17 18	358		doi:10.1016/j.jcms.2010.11.001
19 20	359		
21 22	360		
23 24 25			
26 27			
28 29			
30 31			
32 33			
34 35 26			doi:10.1016/j.jcms.2010.11.001
36 37 38			
39 40			
41 42			
43 44			
45 46			
47 48			
49 50 51			
52 53			
54 55			
56 57			
58 59			Tourseau versions and a latter //langing and hard come /site /shout /au idaling a shtrey 17
60			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml


BMJ Open

2 3	361	Figure 1. Flow diagram for study selection
4 5	362	
6 7	363	WOS, web of science; ME/CFS, myalgic encephalomyelitis/chronic fatigue syndrome.
	363	WOS, web of science; ME/CFS, myalgic encephalomyelitis/chronic fatigue syndrome.
58 59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
00		

$\begin{array}{c}1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\12\\13\\14\\15\\16\\17\\18\\19\\20\\21\\22\\33\\24\\25\\26\\27\\28\\29\\30\\31\\32\\33\\34\\35\\36\\37\\38\\39\\40\\41\\42\\43\\44\\5\\46\\47\\48\\49\\51\\51\\22\\33\\34\\35\\36\\37\\38\\39\\40\\41\\42\\33\\46\\47\\48\\49\\51\\51\\22\\33\\34\\35\\36\\37\\38\\39\\40\\41\\42\\33\\34\\35\\36\\37\\38\\39\\40\\41\\42\\33\\34\\35\\36\\37\\38\\39\\40\\41\\42\\33\\34\\35\\36\\37\\38\\39\\40\\41\\42\\33\\34\\35\\36\\37\\38\\39\\40\\41\\42\\33\\34\\35\\36\\37\\38\\39\\40\\41\\42\\33\\34\\35\\36\\37\\38\\39\\40\\41\\42\\33\\34\\35\\36\\37\\38\\39\\40\\41\\42\\33\\34\\35\\36\\37\\38\\39\\40\\41\\42\\33\\34\\35\\36\\37\\38\\39\\40\\41\\42\\33\\36\\37\\38\\39\\40\\41\\42\\37\\38\\39\\40\\41\\42\\37\\38\\39\\40\\41\\42\\37\\38\\39\\40\\41\\42\\37\\38\\39\\40\\41\\42\\37\\38\\39\\40\\41\\42\\37\\38\\39\\40\\41\\42\\37\\38\\39\\40\\41\\42\\37\\38\\39\\40\\41\\42\\37\\38\\39\\40\\41\\42\\37\\38\\39\\40\\41\\42\\37\\38\\39\\40\\41\\42\\37\\38\\39\\40\\41\\42\\37\\38\\39\\40\\41\\42\\37\\38\\39\\40\\41\\42\\37\\38\\39\\40\\41\\42\\37\\38\\39\\40\\41\\42\\38\\40\\40\\40\\40\\40\\40\\40\\40\\40\\40\\40\\40\\40\\$	
46 47 48 49 50	

365 Table 1. The primary systematic literature search strategy on the electronic databases

Database	Search terms combination
	({epidemiology} OR {prevalence} OR {incidence}) AND ({chronic
Scopus	fatigue syndrome} OR {myalgic encephalomyelitis} OR {myalgic
	encephalomyelitis} OR {CFS/ME})
	("Fatigue Syndrome, Chronic"[Mesh] AND (("Incidence"[Mesh]
PubMed	OR "Epidemiology"[Mesh] OR "epidemiology" [Subheading]) OR
	"Prevalence"[Mesh] OR "Cross-Sectional Studies"[Mesh]))
	("epidemiology" OR "prevalence" OR "incidence") AND ("chronic
Web of science	fatigue syndrome" OR "myalgic encephalomyelitis" OR "CFS/ME"
	OR "ME/CFS")
Mesh, medical s	
Mesh, medical s	ubject headings





254x219mm (300 x 300 DPI)